Conference
Real-world evidence in patient-related outcomes (PROs) of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate plus prednisone (AA+P).
Abstract
196
Background: Oral androgen biosynthesis inhibitor, abiraterone acetate plus prednisone (AA+P), has shown to improve survival and patient-related outcomes (PROs) in clinical trials. The COSMiC study (Canadian Observational Study in Metastatic Cancer of the Prostate; ClinicalTrials.gov: NCT02364531) set out to prospectively amass real-world data on mCRPC patients (pts) managed with AA+P in communities within Canada. Here, we …
Authors
Gotto G; Fradet V; Drachenberg D; Sabbagh R; Rendon RA; Shayegan B; Danielson BL; Casey R; Chan K; Camacho F
Volume
36
Pagination
pp. 196-196
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
February 20, 2018
DOI
10.1200/jco.2018.36.6_suppl.196
Conference proceedings
Journal of Clinical Oncology
Issue
6_suppl
ISSN
0732-183X